A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-13

Study Completion Date

2022-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn what happens to MK-8189 in a healthy person's body over time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)

NCT06687759

Healthy

COMPLETED PHASE1

A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

NCT06826989

Healthy

COMPLETED PHASE1

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

NCT05847439

Healthy Volunteers

COMPLETED PHASE1

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

NCT05284890

Healthy Volunteers

COMPLETED PHASE1

A Study to Investigate the Influence of Hepatic Impairment on MK-8189 Treatment (MK-8189-012)

NCT04676425

Hepatic Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carbon-14 radiolabeled [14C] MK-8189

Participants receive a dose of 4.5-mg immediate release (IR) (\~ 50 μCi) orally on Day 1.

Group Type EXPERIMENTAL

[14C]MK-8189

Intervention Type DRUG

Oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[14C]MK-8189

Oral administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Is in good health based on medical history, physical examination, VS measurements, and ECGs performed before randomization.
* Has a BMI ≥19 and ≤32 kg/m2, inclusive, at screening

Exclusion Criteria

* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
* Has a history of cancer.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes